Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 6
2014 9
2015 12
2016 19
2017 22
2018 25
2019 28
2020 31
2021 35
2022 42
2023 33
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Results by year

Filters applied: . Clear all
Page 1
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D, Switchenko JM, Kahl B, Maddocks K, Grover NS, Qi K, Parisi L, Daly K, Zhu A, Salles G. Martin P, et al. Among authors: switchenko jm. J Clin Oncol. 2023 Jan 20;41(3):541-554. doi: 10.1200/JCO.21.02698. Epub 2022 Jun 28. J Clin Oncol. 2023. PMID: 35763708 Free PMC article.
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul-Naylor JR, Zhong J, Yushak ML, Harvey RD, Paulos CM, Lawson DH, Khan MK, Kudchadkar RR, Buchwald ZS. Qian DC, et al. Among authors: switchenko jm. Lancet Oncol. 2021 Dec;22(12):1777-1786. doi: 10.1016/S1470-2045(21)00546-5. Epub 2021 Nov 12. Lancet Oncol. 2021. PMID: 34780711 Clinical Trial.
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.
Robinson MH, Villa NY, Jaye DL, Nooka AK, Duffy A, McCachren SS, Manalo J, Switchenko JM, Barnes S, Potdar S, Azeem MI, Horvat AA, Parihar VC, Gong J, Liang Y, Smith GH, Gupta VA, Boise LH, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Dhodapkar KM, Dhodapkar MV. Robinson MH, et al. Among authors: switchenko jm. J Clin Invest. 2023 Aug 1;133(15):e167629. doi: 10.1172/JCI167629. J Clin Invest. 2023. PMID: 37526080 Free PMC article.
Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer.
Akce M, Farran B, Switchenko JM, Rupji M, Kang S, Khalil L, Ruggieri-Joyce A, Olson B, Shaib WL, Wu C, Alese OB, Diab M, Lesinski GB, El-Rayes BF. Akce M, et al. Among authors: switchenko jm. J Immunother Cancer. 2023 Oct;11(10):e007235. doi: 10.1136/jitc-2023-007235. J Immunother Cancer. 2023. PMID: 37852737 Free PMC article. Clinical Trial.
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB. Epperla N, et al. Among authors: switchenko j. Blood Adv. 2023 Jun 13;7(11):2287-2296. doi: 10.1182/bloodadvances.2022009225. Blood Adv. 2023. PMID: 36516079 Free PMC article.
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, Hess BT, Isaac KM, Portell CA, Mejia Garcia A, Goldsmith S, Grover NS, Riedell PA, Karmali R, Burkart M, Buege M, Akhtar O, Torka P, Kumar A, Hill BT, Kahl BS, Cohen JB. Sawalha Y, et al. Among authors: switchenko jm. Blood Adv. 2023 Jul 11;7(13):2983-2993. doi: 10.1182/bloodadvances.2022008916. Blood Adv. 2023. PMID: 36809796 Free PMC article.
Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.
Kelvin JM, Jain J, Thapa A, Qui M, Birnbaum LA, Moore SG, Zecca H, Summers RJ, Switchenko JM, Costanza E, Uricoli B, Wang X, Jui NT, Fu H, Du Y, DeRyckere D, Graham DK, Dreaden EC. Kelvin JM, et al. Among authors: switchenko jm. Pharm Res. 2023 Sep;40(9):2133-2146. doi: 10.1007/s11095-023-03596-9. Epub 2023 Sep 13. Pharm Res. 2023. PMID: 37704893
NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.
Maithel SK, Keilson JM, Cao HST, Rupji M, Mahipal A, Lin BS, Javle MM, Cleary SP, Akce M, Switchenko JM, Rocha FG. Maithel SK, et al. Among authors: switchenko jm. Ann Surg Oncol. 2023 Oct;30(11):6558-6566. doi: 10.1245/s10434-023-13809-5. Epub 2023 Jun 27. Ann Surg Oncol. 2023. PMID: 37368098 Free PMC article. Clinical Trial.
227 results